On March 5, Junshi Bio announced that the company received the "Notice of Acceptance" approved and issued by the National Medical Products Administration, and the clinical trial application for JS103 injection was accepted
JS103 is a pegylated uricase derivative independently developed by the company, which is mainly used for the treatment of hyperuricemia with or without gout
JS103 is a pegylated uricase derivative independently developed by the company.
It is mainly used for the treatment of hyperuricemia with or without gout.
It can catalyze the oxidation of uric acid into allantoin, which has a significantly higher solubility than uric acid.
Reduce the effect of blood uric acid
Hyperuricemia is a metabolic syndrome in which excessive uric acid is produced due to the disorder of purine metabolism or the excretion of uric acid is blocked, causing the uric acid in the blood to exceed the critical value
Gout is a crystal-associated joint disease caused by monosodium urate deposition and is directly related to hyperuricemia
According to "China High Urine, the board of directors and all directors guarantee that the content of this announcement does not contain any false records, misleading statements or major omissions, and bear legal responsibility for the authenticity, accuracy and completeness of its content
The Guidelines for the Diagnosis and Treatment of Acidemia and Gout (2019) show that the overall prevalence of hyperuricemia in China is 13.
3%, and that of gout is 1.
Gout and related diseases caused by hyperuricemia are one of the chronic diseases with high incidence in China.
Therefore, the development of JS103 is expected to bring more treatment options to patients